Allergy Asthma Immunol Res.  2014 Jan;6(1):22-26. 10.4168/aair.2014.6.1.22.

Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children

• You SY
• Jwa HJ
• Yang EA
• Kil HR
• Lee JH

• KMID: 2166924
• DOI: http://doi.org/10.4168/aair.2014.6.1.22

Abstract

PURPOSE
Mycoplasma pneumoniae (M. pneumoniae) is one of the most common causes of community-acquired pneumonia in children. The clinical course is typically self-limited and benign; however, rare cases of severe pneumonia can develop despite appropriate antibiotic therapy. We studied the effects of methylprednisolone pulse therapy on severe refractory M. pneumoniae pneumonia in children.
METHODS
The clinical effects of methylprednisolone therapy were evaluated retrospectively in 12 children with severe refractory M. pneumoniae pneumonia, which was diagnosed serologically. All patients developed respiratory distress, high fever, and initial lobar pneumonic consolidation based on radiological findings. All clinical symptoms deteriorated despite appropriate antibiotic therapy. Thus, children were treated with intravenous methylprednisolone pulse therapy in addition to antibiotics.
RESULTS
The average febrile period before admission was 4.9+/-1.7 days, and fever persisted in all children until steroid administration. Methylprednisolone pulse therapy (30 mg/kg) was given 5.4+/-2.5 days after admission. After methylprednisolone pulse therapy, clinical symptoms improved in all patients without adverse events. The fever subsided 0-2 h after initiation of corticosteroid therapy. The abnormal radiological findings resolved within 2.6+/-1.3 days, and the high C-reactive protein levels (6.7+/-5.9 mg/dL) on admission decreased to 1.3+/-1.7 mg/dL within 3.0+/-1.1 days after starting corticosteroid therapy.
CONCLUSIONS
Three-day methylprednisolone pulse therapy could be applied to treatment of refractory M. pneumoniae pneumonia despite appropriate antibiotic therapy and appeared to be efficacious and well-tolerated.

Keyword

Children; methylprednisolone; Mycoplasma pneumoniae; pneumonia

MeSH Terms

Anti-Bacterial Agents
C-Reactive Protein
Child*
Fever
Humans
Methylprednisolone*
Mycoplasma pneumoniae*
Mycoplasma*
Pneumonia*
Pneumonia, Mycoplasma*
Retrospective Studies
Anti-Bacterial Agents
C-Reactive Protein
Methylprednisolone

Figure

• 

  Fig. 1 Defervescence was observed in all children after methylprednisolone pulse therapy. (A) Body temperature data were analyzed using repeated-measures ANOVA (P<0.001). (B) Decreasing serum CRP levels were observed in all children after methylprednisolone pulse therapy. CRP concentrations were analyzed using repeated-measures ANOVA (P<0.001). *The one day before admission. †The day on admission. ‡The first day of admission. §The second day of admission. ∥The third day of admission. ¶The 4.3±2.3 day of admission (before steroid pulse therapy). **The 8.3±2.0 day of admission (after steroid pulse therapy). CRP, C-reactive protein; HD, hospital day.

• 

  Fig. 2 Chest radiographs of patient 4. (A) Chest radiography upon admission showed consolidation of the left lower lobe with pleural effusion. (B) Before methylprednisolone pulse therapy, the radiographic findings remained unchanged with deteriorated clinical signs at hospital day 3. (C) Chest radiography showed resolution of consolidation of the left lower lobe and decreased pleural effusion on the day after initiation of methylprednisolone pulse therapy at hospital day 4. (D) hospital day 7.

Reference

1. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004; 17:697–728.

2. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008; 32:956–973.

3. Heiskanen-Kosma T, Korppi M, Jokinen C, Kurki S, Heiskanen L, Juvonen H, Kallinen S, Stén M, Tarkiainen A, Rönnberg PR, Kleemola M, Mäkelä PH, Leinonen M. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J. 1998; 17:986–991.

4. Sinaniotis CA, Sinaniotis AC. Community-acquired pneumonia in children. Curr Opin Pulm Med. 2005; 11:218–225.

5. Chan ED, Welsh CH. Fulminant Mycoplasma pneumoniae pneumonia. West J Med. 1995; 162:133–142.

6. Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther. 2008; 6:509–521.

7. Lee SH, Noh SM, Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Lee BC. Clinico-epidemiologic study of Mycoplasma pneumoniae pneumonia (1993 through 2003). Korean J Pediatr. 2005; 48:154–157.

8. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010; 16:78–86.

9. Shimizu T, Kida Y, Kuwano K. Cytoadherence-dependent induction of inflammatory responses by Mycoplasma pneumoniae. Immunology. 2011; 133:51–61.

10. Lu A, Wang L, Zhang X, Zhang M. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid. Pediatr Pulmonol. 2011; 46:1093–1097.

11. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008; 57:223–228.

12. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, Lee BC. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2006; 41:263–268.

13. Ferwerda A, Moll HA, de Groot R. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures. Eur J Pediatr. 2001; 160:483–491.

14. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis. 2000; 31:1507–1511.

15. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol. 2008; 3:635–648.

16. Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev. 2004; 15:157–168.

17. Denny FW, Taylor-Robinson D, Allison AC. The role of thymus-dependent immunity in Mycoplasma pulmonis infections of mice. J Med Microbiol. 1972; 5:327–336.

18. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, Gomez AM, Esposito S, Principi N, Hardy RD. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis. 2008; 198:1180–1188.

19. De Pascale G, Bello G, Antonelli M. Steroids in severe pneumonia: a literature review. Minerva Anestesiol. 2011; 77:902–910.

20. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005; 353:1711–1723.

21. Niitu Y, Hasegawa S, Suetake T, Kubota H, Komatsu S, Horikawa M. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J Pediatr. 1970; 76:438–443.

22. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, Sasaki Y, Arakawa Y, Sasaki T. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001; 45:617–620.

23. Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 2011; 6:423–431.

24. Oh CE, Choi EH, Lee HJ. Detection of genetic mutations associated with macrolide resistance of Mycoplasma pneumoniae. Korean J Pediatr. 2010; 53:178–183.